2026 outlook11 Mar 2026 10:01
A Review of an Exciting 2025
2025 has been a year of focused scientific progress and continued advancement of Genflow
Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform.
Across our portfolio, we have maintained momentum in both animal health where progress in our
canine study may provide translational insights relevant to future human applications as well as
therapeutic development for dogs.
These advancements have been supported by a strengthened network of leading academic
collaborators and laboratories. Together, with continued backing from international institutional
investors and previously awarded government grants, this ecosystem helped accelerate Genflow's
scientific and clinical development throughout 2025.
Program Highlights
We've made a number of notable strides across our programs this year, including:
· Dog Aging (GF-1004)
We made significant strides in our clinical trial for aging dogs with full administration of our
investigational SIRT6-based gene therapy now completed. No adverse events were reported
during the dosing phase of the study, with no serious, moderate, or minor side effects
observed. The study which began in March 2025, is being conducted as a blinded clinical
trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle
biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-
associated biomarkers.
Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment
planned at the six-month timepoint and results expected in June-July 2026 to evaluate
durability and longer-term effects.
· MASH (GF-1002)
Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed
early-stage MASH, patients with advanced fibrosis - roughly one-third of the population -
still face limited treatment options. In response, we repositioned GF-1002 to target this high-
need group, leveraging its antifibrotic properties and potential to prevent progression to
cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the
prevention of HCC.
We are now finalizing our IND package and evaluating mRNA/LNP delivery as an
alternative to AAV, an approach that could enable repeat dosing and lower manufacturing
costs. Encouraging data continue to support this next phase of research and development.
· Glaucoma
In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise
in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage
intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data
suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve
function, shifting the focus from symptom control to true neuroprotection.
We are advancing discussions with a leading LNP partner to support delivery innovation in
this s
Sign In
Follow the stocks
